Publicaciones Imprimir Blomquist MR, Eghlimi R, Beniwal A, Grief D, Nascari DG, Inge L, Sereduk CP, Tuncali S, Roos A, Inforzato H, Sharma R, Pirrotte P, Mehta S, Fortin Ensign SP, Loftus JC, Tran NL. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma. Int J Mol Sci. 2024 Jun 6; 25 (11) Epub 2024 June 06 View PubMed Gaulin C, Craig F, Fortin Ensign S, Robetorye R, Gibson S, Kelemen K, Khera N, Leis J, Tsang M, Rosenthal A, Munoz J, Palmer J, Hilal T. Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms. Leuk Lymphoma 2023 Dec; 64 (14):2347-2350 Epub 2023 Sept 07 View PubMed Huff D, Fortin Ensign S, Ryan MS, Palmer J, Munoz J. Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review. J Immunother Precis Oncol. 2023 Nov; 6 (4):198-202 Epub 2023 Dec 02 View PubMed Hu LS, D'Angelo F, Weiskittel TM, Caruso FP, Fortin Ensign SP, Blomquist MR, Flick MJ, Wang L, Sereduk CP, Meng-Lin K, De Leon G, Nespodzany A, Urcuyo JC, Gonzales AC, Curtin L, Lewis EM, Singleton KW, Dondlinger T, Anil A, Semmineh NB, Noviello T, Patel RA, Wang P, Wang J, Eschbacher JM, Hawkins-Daarud A, Jackson PR, Grunfeld IS, Elrod C, Mazza GL, McGee SC, Paulson L, Clark-Swanson K, Lassiter-Morris Y, Smith KA, Nakaji P, Bendok BR, Zimmerman RS, Krishna C, Patra DP, Patel NP, Lyons M, Neal M, Donev K, Mrugala MM, Porter AB, Beeman SC, Jensen TR, Schmainda KM, Zhou Y, Baxter LC, Plaisier CL, Li J, Li H, Lasorella A, Quarles CC, Swanson KR, Ceccarelli M, Iavarone A, Tran NL. Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nat Commun. 2023 Sep 28; 14 (1):6066 Epub 2023 Sept 28 View PubMed Ensign SF, Agarwal M, Klanderman M, Badawy M, Halfdanarson TR, Johnson DR, Sonbol MB, Kendi AT. Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions. Nucl Med Commun. 2023 Jul 1; 44 (7):663-670 Epub 2023 May 08 View PubMed Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro Oncol. 2023 Jan 5; 25 (1):28-36 View PubMed Thomson HM, Fortin Ensign SP, Edmonds VS, Sharma A, Butterfield RJ 3rd, Schild SE, Ashman JB, Zimmerman RS, Patel NP, Bryce AH, Vora SA, Sio TT, Porter AB. Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma. Clin Med Insights Oncol. 2023; 17:11795549231161878. Epub 2023 Mar 21. View PubMed Fortin Ensign SP, Gaulin C, Hrachova M, Ruff M, Harahsheh E, Vicenti K, Castro J, Munoz J, Rosenthal A, Mrugala MM. Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Curr Treat Options Oncol. 2022 Dec; 23 (12):1845-1860 Epub 2022 Dec 16 View PubMed Fortin Ensign SP, Gathers D, Wiedmeier JE, Mrugala MM. Central Nervous System Lymphoma: Novel Therapies. Curr Treat Options Oncol. 2022 Jan; 23 (1):117-136 Epub 2022 Feb 19 View PubMed Fortin Ensign SP, Yancey E, Anderson KS, Mrugala MM. Safety and Feasibility of Intrathecal Pembrolizumab Infusion in Refractory Triple Negative Breast Cancer with Leptomeningeal Disease: A Case Report. Current Problems in Cancer: Case Reports. 2021; 4:100103. Epub 2021 Jul 21. Fortin Ensign S, Hrachova M, Chang S, Mrugala MM. Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members. Neurooncol Pract. 2021 Jun; 8 (3):310-316 Epub 2021 Feb 17 View PubMed Ding Z, Dong Z, Yang Y, Fortin Ensign SP, Sabit H, Nakada M, Ruggieri R, Kloss JM, Symons M, Tran NL, Loftus JC. Leukemia-Associated Rho Guanine Nucleotide Exchange Factor and Ras Homolog Family Member C Play a Role in Glioblastoma Cell Invasion and Resistance. Am J Pathol. 2020 Oct; 190 (10):2165-2176 Epub 2020 July 18 View PubMed Fortin Ensign S, Bollin K, Millis SZ, Hinds BR, Kosty M, Uchiyama C. Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas. Pigment Cell Melanoma Res. 2020 May; 33 (3):458-465 Epub 2019 Dec 18 View PubMed Blomquist MR, Ensign SF, D'Angelo F, Phillips JJ, Ceccarelli M, Peng S, Halperin RF, Caruso FP, Garofano L, Byron SA, Liang WS, Craig DW, Carpten JD, Prados MD, Trent JM, Berens ME, Iavarone A, Dhruv H, Tran NL. Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. Neurooncol Adv. 2020 Jan-Dec; 2 (1):vdaa078 Epub 2020 June 19 View PubMed McAuliffe L, Fortin Ensign S, Larson D, Bavaro M, Yetto J, Cathey M, Mukaigawara M, Narita M, Ohkusu K, Quast T, Volk C. Severe CNS angiostrongyliasis in a young marine: a case report and literature review. Lancet Infect Dis. 2019 Apr; 19 (4):e132-e142 Epub 2018 Nov 16 View PubMed Fortin Ensign S, Baca-Motes K, Steinhubl SR, Topol EJ. Characteristics of the modern-day physician house call. Medicine (Baltimore). 2019 Feb; 98 (8):e14671 View PubMed Ensign SP, Roos A, Mathews IT, Dhruv HD, Tuncali S, Sarkaria JN, Symons MH, Loftus JC, Berens ME, Tran NL. SGEF Is Regulated via TWEAK/Fn14/NF-kappaB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide. Mol Cancer Res. 2016 Mar; 14 (3):302-12 Epub 2016 Jan 13 View PubMed Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL. FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis. 2014 Aug; 31: (6)613-23. View PubMed Fortin Ensign SP, Mathews IT, Symons MH, Berens ME, Tran NL. Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression. Front Oncol. 2013 Oct 04; 3: 241. View PubMed Fortin Ensign SP, Mathews IT, Eschbacher JM, Loftus JC, Symons MH, Tran NL. The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2. J Biol Chem. 2013 Jul 26; 288: (30)21887-97. View PubMed Kwiatkowska A, Didier S, Fortin S, Chuang Y, White T, Berens ME, Rushing E, Eschbacher J, Tran NL, Chan A, Symons M. The small GTPase RhoG mediates glioblastoma cell invasion. Mol Cancer. 2012 Sep 11; 11:65. View PubMed Fortin SP, Ennis MJ, Schumacher CA, Zylstra-Diegel CR, Williams BO, Ross JT, Winkles JA, Loftus JC, Symons MH, Tran NL. Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells. Mol Cancer Res. 2012 Jul; 10: (7)958-68. View PubMed Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F. Galectins and Gliomas. Brain Pathol. 2010 Jan; 20(1):17-27. Fortin S, Le Mercier M, Camby I, Spiegl-Kreinecker S, Berger W, Lefranc F, Kiss R. Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells. Brain Pathol. 2010 Jan; 20 (1):39-49 Epub 2009 Oct 08 View PubMed Fortin SP, Ennis MJ, Savitch BA, Carpentieri D, McDonough WS, Winkles JA, Loftus JC, Kingsley C, Hostetter G, Tran NL. Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res. 2009 Nov; 7: (11)1871-81. View PubMed Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, Kiss R. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia. 2009 May; 11 (5):485-96 View PubMed Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, Black MA, McDonough WS, Fortin SP, Niska JR, Winkles JA, Cunliffe HE. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res. 2008 May; 6: (5)725-34. View PubMed Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, Nakada M, Cunliffe HE, Hostetter G, Hoelzinger DB, Rennert JL, Michaelson JS, Burkly LC, Lipinski CA, Loftus JC, Mariani L, Berens ME. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res. 2006 Oct 01; 66: (19)9535-42. View PubMed PST-20537596 Inicio Publicaciones